Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Autophagy Inhibitor Development Services for Cancer

Alfa Cytology is a company focused on providing comprehensive preclinical research and development services for the advancement of cancer therapies. We delve into key cellular processes associated with cancer cell survival and therapy resistance, with the aim of helping to discover and optimize novel autophagy inhibitors for use in cancer therapy, meeting the needs of a wide range of research organizations and companies involved in therapeutic development.

Overview of Autophagy Inhibitor Development for Cancer

Autophagy is a highly conserved catabolic process that can be activated in response to a variety of stresses, including nutrient deprivation, hypoxia, and oxidative stress, and its primary role is to recycle dysfunctional cellular components. Autophagy inhibitors are drugs or compounds used to block the autophagy process, preventing cancer cells from utilizing autophagy as a survival mechanism and sensitizing them to cancer treatments, capable of hindering tumor growth and enhancing the efficacy of existing therapies, and a promising strategy for cancer treatment.

Fig. 1 Role of cancer-related factors regulating autophagy in tumor suppression. Fig.1 Cancer-associated factors that regulate autophagy and their multiple roles in tumor suppression. (Debnath, J., et al., 2023)

Autophagy inhibitors can target various stages of the autophagic process, including autophagosome formation, lysosomal function, and autophagosome-lysosome fusion. However, cancer cells often develop resistance to autophagy inhibitors, limiting their efficacy in the clinic. Understanding the molecular mechanisms of drug resistance and developing strategies to overcome it are key research hotspots in this field.

Autophagy Inhibitor Development Targets

Currently, autophagy inhibitors targeting the following four targets are being hotly investigated, and the types of molecules under development include small molecule inhibitors, monoclonal antibodies, polyclonal antibodies, vaccines, and others.

VPS34

mTOR

Beclin 1

Our Services

With our vast experience, expertise and team of specialists, Alfa Cytology's goal is to provide a one-stop solution for the development of autophagy inhibitors and accelerated translation of promising drug candidates.

Our One-stop Service Programs

Our comprehensive services are but not limited to the following.

Target Validation and Inhibitor Screening

Identify novel autophagy targets and screen potential autophagy inhibitors using advanced bioinformatics and high-throughput screening (HTS) platforms.

Autophagy Inhibitor Design and Optimization

Design and optimize inhibitors with improved binding affinity and selectivity using molecular modeling and computational modeling.

In Vitro and In Vivo Efficacy Studies

Rigorous preclinical studies using a range of cellular and animal models to evaluate the efficacy of autophagy inhibitors in inhibiting tumor growth and metastasis.

Lead Compound Optimization

We optimize lead compounds for enhanced potency, selectivity, and pharmacokinetic properties through structure-effect relationship (SAR) studies and medicinal chemistry approaches.

ADME Analysis

Thorough ADME (absorption, distribution, metabolism, and excretion) analyses are performed on identified inhibitors to evaluate their pharmacokinetic properties to guide further development.

Alfa Cytology offers a comprehensive approach to accelerate the discovery and optimization of cancer therapies. We are primarily a one-stop shop and solution provider for researchers engaged in the development of next-generation therapies around the world. Contact us today to learn more about how we can accelerate the development of your cancer therapies.

Reference

Debnath, J., et al.; (2023). Autophagy and autophagy-related pathways in cancer. Nature reviews Molecular cell biology, 24(8), 560-575.

For research use only.